This is a review on 11 original studies that reported outcomes of 544 rhabdomyosarcoma (RMS) children and adolescent patients who received PBT. The 5-year rates of LC, PFS and OS were 84%, 76% and 82%. Acute and late toxicities were mainly grades 1 to 2 in all studies. The authors concluded that this data has showed that PBT is a feasible, safe, and effective modality for RMS, showing promising LC, OS, PFS, and lower acute and late toxicities.